Biote cuts FY25 revenue view to over $190M from $202M-$208M

Consensus $204.7M. The company states: “Given the time it will take for our changes to begin to have a positive impact, we are adjusting our fiscal 2025 revenue guidance to be greater than $190 million, as compared to the previously disclosed range of $202-$208 million, and revising our fiscal 2025 Adjusted EBITDA guidance to be greater than $50 million, as compared to the previously disclosed range of $59-$64 million. This revised guidance reflects the impacts we are experiencing as we continue to reorganize our commercial organization and drive towards our strategic priorities. The restructuring actions we are taking represent decisive steps forward for Biote (BTMD), and we are executing with focus and conviction to achieve our strategic goals. Our liquidity remains strong and we intend to continue to invest in our value proposition to gain and retain practitioners. Biote remains committed to advancing patient health by transforming healthy aging, and I am confident that we are on the right path to achieve our vision while building long-term value for all stakeholders.”